Accessibility Tools

Texas General Contracting
Texas General Contracting
Texas General Contracting
Texas General Contracting
Texas General Contracting
Texas General Contracting
Texas General Contracting
Texas General Contracting
retina-vitreous-of-texas-01.jpg
retina-vitreous-of-texas-02.jpg
retina-vitreous-of-texas-03.jpg
retina-vitreous-of-texas-04.jpg
retina-vitreous-of-texas-05.jpg
retina-vitreous-of-texas-06.jpg
retina-vitreous-of-texas-07.jpg
retina-vitreous-of-texas-08.jpg

Clinical Trials

Gather2 ISEE2008 –  Iveric Bio [Enrollment Closed]

A Phase 3, multicenter, randomized, double-masked shamcontrolled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration

TENAYA - GR40306 - Genentech Roche

A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety faricimab in patients with neovascular age-related macular degeneration. 

Pavilion GR41675 – Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranizumab in patients with Diabetic Retinopathy

Condor: CRTH258D2301 – Novartis [Enrollment Closed]

Novartis pharmaceuticals trail entitled: A 96-week, two-arm, randomized single-masked, multi-center, Phase III study assessing the efficacy and safety of Brolucizumab 6mg compared to Panretinal Photocoagulation Laser in patients with Proliferative Diabetic Retinopathy.

Balaton – GR41984 - Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized, Double-Masked, Active comparator - controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Branch Retinal Vein Occlusion 

Comino- GR41986  – Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized, Double-Masked, Active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Central Retinal or Hemiretinal Vein Occlusion.

SCORE2 - NIH (National Eye Institute)     2014 – 2016

Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks. 2014-2016

Phase 1 DME-Genentech Roche [Enrollment Open]

A Phase I, Multicenter, Open-label study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of RO7446603 alone and co-administered with aflibercept in patients with Diabetic Macular Edema.

Elevatum- Genentech Roche [Enrollment Open]

A Phase IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (ro6867461) treatment response in treatment-naïve, underrepresented patients with diabetic macular edema.

Pagoda GR40550 - Genentech Roche [Enrollment Closed] 

A Phase III, Multicenter, Randomized, visual assessor masked, active comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema.   

Rhone-X GR41987 – Genentech - Roche [Enrollment Closed]

A Multicenter, open-Label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema.

YOSEMITE - GR40349- Genentech Roche [Trial Completed]

A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.

COOL-3 - RecensMedical Inc [Trial Completed]

A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia for Local Anesthesia among Patients Receiving Intravitreal Injections. 

  • Diabetic Retinopathy in HIV Subjects Treated with EGRIFTA

  • Treatment for center-involved DME in Eyes with Very Good Visual Acuity

  • Short-term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes

  • Lucentis – Avastin Trial Design

  • Protocol “L”: Evaluation of Visual Acuity Measurements in Eyes with Diabetic Macular Edema

  • Protocol “N”: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy

  • Mild Macular Grid (MMG) for Diabetic Macular Edema

  • Steroid Injection for Diabetic Macular Edema

  • Vitrectomy for Diabetic Macular Edema

  • Peribulbar Triamcinolone

  • PRP for Diabetic Macular Edema

  • Subclinical Diabetic Macular Edema

  • Anecortave Acetate for Wet AMD

  • Anecortave Acetate for Dry AMD

  • Surgical Therapeutics for Epiretinal Membranes and Vitrectomy

  • Branch Vein Occlusion Sheathotomy Study

  • Vit 100 (VitrenAse) Study for PVR

  • Oral treatment of Diabetic Retinopathy (Lilly)

  • Photodynamic Therapy (PDT) Study – Approved by FDA 4/2000

  • Macular Translocation for CNV

  • Perfluoron (PFO) Phase IV Clinical Trial

  • Submacular Surgery Pilot Trials (SST)

  • Perfluoron Study (PFO)

  • Syntex Ganciclovir Implant Trials

  • ISIS CMV Retinitis Trials

  • RPE Transplantation Study

  • Collaborative Ocular Melanoma

  • COMS

  • Macular Photocoagulation Study (MPS)

  • IOP Vitrectomy Study

  • Age-Related Eye Disease Study

  • Richard-James Silicone Oil Study

  • Vitrectomy for Macular Hole Study

  • Endophthalmitis Vitrectomy Study (EVS)

  • Advanced ROP Study